New oral medication to help treat cocaine addiction
PDE7 Inhibitor for the Treatment of Cocaine Use Disorder
This study is testing a new pill called OMS182399 that aims to help people struggling with cocaine use by reducing cravings and restoring balance in the brain, since there aren't any approved medications for this condition right now.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Omeros Corporation NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11059141 on NIH RePORTER |
What this research studies
This research aims to develop an oral medication called OMS182399 to treat cocaine use disorder (CUD). Currently, there are no approved drug treatments for CUD, and most patients only receive psychosocial therapies, which often lead to high dropout rates. The medication works by selectively inhibiting a specific enzyme (PDE7) to help restore the balance of dopamine in the brain, potentially reducing cravings for cocaine. The project will involve preclinical studies and clinical trials to assess the safety and effectiveness of this new treatment in individuals with CUD.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with cocaine use disorder.
Not a fit: Patients who are not struggling with cocaine addiction or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a much-needed pharmacological treatment option for individuals struggling with cocaine addiction.
How similar studies have performed: While there have been various approaches to treating addiction, this specific PDE7 inhibitor is a novel approach and has not been widely tested in clinical settings for cocaine use disorder.
Where this research is happening
Seattle, United States
- Omeros Corporation — Seattle, United States (Active)
Researchers
- Principal investigator: Gaitanaris, George — Omeros Corporation
- Study coordinator: Gaitanaris, George
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.